support this Website with an
unrestricted educational grant.
About EURAMOS
EURAMOS is the European and American Osteosarcoma Study Group. The study was founded in 2001.
This website contains information about Osteosarcoma and the current EURAMOS I Trial.
To read more about EURAMOS click here.
If you have any questions regarding the EURAMOS 1 trial or any difficulties using this website, please contact euramos1@ctu.ac.uk
What's New?
March 2010
Future Clinical Trials for Adjuvant Treatment of Osteosarcoma – Prioritising the Questions
With the EURAMOS-1 trial already having recruited more than two-thirds of its patients and with less than 1 year left until the end of patient recruitment, the EURAMOS collaborators are keen to develop strategies on how to continue performing successful multinational trials for patients with osteosarcoma. This may only be accomplished together with other investigators and groups who are facing similar challenges as well as with trial support networks.
To this end, a two-day international conference was held in London, UK on the 15th and 16th March 2010 to reflect on recent considerations, review pertinent questions and consider how best to work to address outstanding clinical questions.
Around fifty clinicians, statisticians and trialists participated in the meeting, representing leading osteosarcoma research groups from all over the world including ASSG, COG, COSS, EOI, EORTC, EURAMOS, GEIS, ISG, JCOG, SARC, SFCE and SSG.
Click here for more information on the Bone Planning Meeting...
1000th EURAMOS-1 Patient Randomised
EURAMOS-1 has reached an important milestone by randomising its 1000th patient. This took place on the 29th March 2010 at the University of Miami, School of Medecine, USA, participating via the Children's Oncology Group (COG).
Thank you to all participating centres for helping to achieve this important goal, and for your continued support of the EURAMOS-1 trial.
November 2009
Dr. Dorothe Carlle recently gave a presentation on the EURAMOS-1 collaboration at the 15th Annual Meeting of Connective Tissue Sarcoma Society (CTOS) in Miami, Florida between the 5th and 7th November 2009CTOS is an international group comprised of physicians, scientists and clinical investigators with a primary interest in the tumours of connective tissues. The 15th Annual Meeting of CTOS was held in Miami and attended by more than four hundred sarcoma experts from various specialities all over the world. The presentation was part of the session on adolescent and young adult sarcomas and was and excellent opportunity to inform about the progress and success of the EURAMOS-1 trial.
Please click here to open presentation
May 2009
Peg-Intron for good responders
Mark Bernstein, Chief Investigator for the COG group, has
provided a very useful paragraph on the use of interferon therapy in
the treatment of osteosarcoma along with several useful links to
supporting publications.
Please click here to open the document.
April 2009
Recruitment to EURAMOS-1 has been extended until around June 2010
The target recruitment for EURAMOS-1 was a minimum of 1260 patients
randomised to the trial; of these, 567 would likely be good responders
and 693 poor responders. It was anticipated that around 1400 patients
would need to be registered to achieve 1260 randomisations. However,
there has been a lower than expected randomisation rate in the trial.
This has been due to many reasons including disease progression,
insufficient preoperative chemotherapy and withdrawal of consent. This
means that more patients will need to be registered than first
anticipated in order to achieve the required randomisation target of
1260 patients.
The decision therefore has been made by EURAMOS-1 Trial Management
Group, in agreement with the Trial Steering Committee and Independent
Data Monitoring Committee, to extend the recruitment period to
EURAMOS-1 by approximately one year. This is based on calculations
showing that around 2000 patients would need to be registered to attain
the planned power for the trial’s main comparisons.
Based on experience in previous trials, the four participating groups
expect to register around 400 patients per year in total. Thus, the
trial will be extended by one year, so the expected closure date to
registration will now be June 2010. The results of the primary outcome
measure, event-free survival, should be known two to four years after
the trial closes to accrual.
The amendment was approved by UK Ethics and Regulatory Authorities in
early 2009. Submissions in collaborative international groups are
currently in progress.
March 2009
Team Update
EURAMOS-1 Trial Manager Monique Tomiczek has left the MRC CTU for a
year to go travelling. We would like to take this opportunity to thank
Monique for all her hard work on the trial and wish her the best for
the coming year!
Sarah Beall has now joined the EURAMOS-1 team as Trial Manager. Her contact details can be found below:
T: +44 (0)207 607 4617
E: euramos@ctu.mrc.ac.uk
F: +44 (0)207 670 4818
March 2009
We would like to draw your attention to the following conference:
EMSOS 2009: 14th – 15th May 2009. Stuttgart, Germany
The European Musculo-Skeletal Oncology Society (EMSOS) meeting will
provide delegates with an opportunity to gain state of the art
knowledge on the current diagnosis and treatment of bone and soft
tissue sarcoma. This meeting is open to both EMSOS and non EMSOS
members and is relevant to everyone working in the field of
musculoskeletal tumour management.
Further information can be found on the EMSOS website here: http://www.emsos2009.de
Bringing Medicine to Life
Images from the Art Project are on
permanent display at the Wellcome Trust 'Medicine Now' Gallery, located
on the first floor of Wellcome Collection Conference Centre, 183 Euston
Road, London
Click here to read more about the Art Project.
A project inspired by the MRC Clinical Trials Unit in collaboration
with Dr Martha Perisoglou in the University College Hospital, London.
Members
New Applicant Countries
EURAMOS I is no longer accepting applications from new
countries wishing to join the trial but welcomes expressions of interest from
national representatives wishing to participate in future EURAMOS
collaborations. Please contact us on euramos1@ctu.mrc.ac.uk
Participating Instituitions in EURAMOS I can access detailed trial information through the password-protected members sections.
Click here to access the Participating Instituitions section.
Trial Management Group
Trial Management Group members can all the documents in the members' password-protected sections
To access the Trial Management Group section Click here.
In focus
Scandinavian Sarcoma Group (SSG)
The Scandinavian Sarcoma Group (SSG) comprises the Scandinavian countries (Denmark, Finland, Iceland, Norway and Sweden) with a population of about 25 million people.
Since 1979, SSG has performed three non-randomized neo-adjuvant chemotherapy trials for high-grade osteosarcoma localized to the extremities.
Our Collaborators
